Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,801 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
Murakami H, Handa H, Abe M, Iida S, Ishii A, Ishikawa T, Ishida T, Oota M, Ozaki S, Kosaka M, Sakai A, Sawamura M, Shimazaki C, Shimizu K, Takagi T, Hata H, Fukuhara T, Fujii H, Miyata A, Wakayama T, Takatsuki K. Murakami H, et al. Among authors: ishida t. Eur J Haematol. 2007 Sep;79(3):234-9. doi: 10.1111/j.1600-0609.2007.00908.x. Epub 2007 Jul 26. Eur J Haematol. 2007. PMID: 17655699 Clinical Trial.
Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies.
Kurosawa M, Yonezumi M, Hashino S, Tanaka J, Nishio M, Kaneda M, Ota S, Koda K, Suzuki N, Yoshida M, Hirayama Y, Takimoto R, Torimoto Y, Mori A, Takahashi T, Iizuka S, Ishida T, Kobayashi R, Oda T, Sakai H, Yamamoto S, Takahashi F, Fukuhara T. Kurosawa M, et al. Among authors: ishida t. Int J Hematol. 2012 Dec;96(6):748-57. doi: 10.1007/s12185-012-1210-y. Epub 2012 Oct 31. Int J Hematol. 2012. PMID: 23111539
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. Watanabe T, et al. Among authors: ishida t. Br J Haematol. 2016 Mar;172(5):745-56. doi: 10.1111/bjh.13900. Epub 2016 Jan 5. Br J Haematol. 2016. PMID: 26732066 Free PMC article. Clinical Trial.
[IgE-κ type multiple myeloma achieving complete response with novel agents].
Takei T, Ishida T, Ikeda M, Shingaki S, Miyazaki K, Yoshiki Y, Abe Y, Okazuka K, Iki S, Tsukada N, Suzuki K. Takei T, et al. Among authors: ishida t. Rinsho Ketsueki. 2017;58(11):2232-2237. doi: 10.11406/rinketsu.58.2232. Rinsho Ketsueki. 2017. PMID: 29212974 Review. Japanese.
4,801 results